Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Chu

Pediatric Gastroenterology San Diego, CA Medical Doctor

NPI 1912369273 CMS profile 11304641

3030 Childrens Way, San Diego, CA 92123

Open in the dashboard

General payments

$8,012

45 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Chu of San Diego, CA is reported in the CMS Open Payments database as having received $8,012 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $614 7
2024 General $6,432 23
2023 General $767 12
2022 General $5 1
2021 General $194 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Chu
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Christopher Chu were reported at $614. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Christopher Chu Pediatric Gastroenterology median Middle half National median
2019 $0 $131 $41–$311 $163
2020 $0 $79 $23–$223 $114
2021 $194 $104 $32–$321 $132
2022 $5 $125 $37–$331 $149
2023 $767 $169 $55–$440 $160
2024 $6,432 $196 $73–$563 $164
2025 $614 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mirum Pharmaceuticals, Inc. $6,087 13 payments
  2. Boston Scientific Corporation $591 4 payments
  3. Alcresta Therapeutics, Inc. $270 3 payments
  4. AbbVie, Inc. $194 2 payments
  5. Kiniksa Pharmaceuticals, Ltd. $166 6 payments
  6. CONMED Corporation $164 3 payments
  7. Regeneron Healthcare Solutions, Inc. $157 2 payments
  8. Kiniksa Pharmaceuticals International, plc $146 5 payments
  9. Genzyme Corporation $73 3 payments
  10. Ipsen Biopharmaceuticals, Inc $70 1 payment
  11. Other $94 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $5,200 2 payments
  2. Food and Beverage $2,596 37 payments
  3. Travel and Lodging $155 4 payments
  4. Education $61 2 payments
Products named General payments · program years 2021–2025
  1. Livmarli $6,087 13 payments
  2. EMBLEM MRI S-ICD $319 2 payments
  3. Arcalyst $312 11 payments
  4. LUX-Dx Insertable Cardiac Monitor $272 2 payments
  5. RELIZORB $270 3 payments
  6. HUMIRA $194 2 payments
  7. CONMED HEMOSTASIS $164 3 payments
  8. DUPIXENT Inflammation And Immunology $126 1 payment
  9. CONMED BILIARY $125 1 payment
  10. DUPIXENT Immunology $73 3 payments
  11. Other $302 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record